Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (136)	12/6/2001 11:42:25 AM
From: tuck	Read Replies (1) \| Respond to of 897

Answering my own question; no. IVGN is likely going to acquire something, namely a reagent company. Who knows what might happen? Since they have the cash in hand, they could just pay cash, and there's a lot of cheap stuff out there now. EBIO, TWTI, TECH, even QGENF are possible targets, but the latter two would be pretty big, and IVGN's price would likely suffer. The former two are small and pretty good fits, IMO. The market might like those deals (though IVGN not likely to rocket on such news; just not get whacked). Anyhow, more interested in HGSI as a near-term short. It has been noted that they will discuss clinical news wrt reperfermin on Friday at 5:00PM. Has good news ever come out at such a time? Thanks to Peter and others on the Valuation thread for the idea. If it is bad news, it might be a good time to buy HGSI if you believe in their in their other programs, since the stock has already been weak of late. Anybody interested in seeing an actual portfolio here? Would it generate more discussion? I'm willing to risk the public embarrassment (though as I type, the portfolios I run are roughly even, which is better than what the NAZ can say over the same time periods; I'm not that embarrassed). Cheers, Tuck